Plataforma BIOBADASER III

Registro Español de Acontecimientos Adversos de Terapias Dirigidas en Enfermedades Reumáticas

Biobadaser Fase III

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care & Research, 2022.

06/07/2022

Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ,Bjorn Gudbjornsson B,Catalin Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG,Carlos Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML

doi: 10.1002/acr.24560